8-K - IMDX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 15, 2022

OncocyteCorporation

(Exact name of registrant as specified in its charter)

California	1-37648	27-1041563
(State<br> or other jurisdiction	(Commission	(IRS<br> Employer
of<br> incorporation)	File<br> Number)	Identification<br> No.)

15Cushing

Irvine,California 92618

(Address of principal executive offices)

(949)409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common<br> Stock, no par value	OCX	The<br> Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Forward-LookingStatements

Anystatements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,”“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)should be considered to be forward-looking statements. Factors that could cause actual results to differ materially from the resultsanticipated in these forward-looking statements are contained in Oncocyte Corporation’s Annual Report on Form 10-K filed with theSecurities and Exchange Commission (“SEC”) under the heading “Risk Factors” and in other filings that Oncocytemay make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they aremade, and the facts and assumptions underlying these statements may change. Except as required by law, Oncocyte disclaims any intentor obligation to update these forward-looking statements.

Referencesto “Oncocyte,” the “Company,” we,” “us,” and “our” are references to Oncocyte Corporation.

Item7.01 - Regulation FD Disclosure.

On July 15, 2022, Oncocyte will deliver a presentation at its 2022 Annual Meeting of Shareholders, which will also be made available on its website. A copy of the presentation is being furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information contained in this Item, including the Exhibit attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

Item9.01 - Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Annual Meeting Presentation
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ONCOCYTE CORPORATION
Date:<br> July 15, 2022	By:	/s/ Ronald Andrews
		Ronald<br> Andrews
		Chief<br> Executive Officer

Exhibit 99.1